| Abstrakt: |
A study conducted at Tel Aviv Medical Center in Israel compared the effectiveness of early treatment with 6-mercaptopurine (6-MP) and adalimumab in preventing postoperative recurrence (POR) in patients with Crohn's disease (CD). The study enrolled 35 patients who had undergone ileocecectomy and found that patients treated with adalimumab had significantly lower rates of endoscopic recurrence (ePOR) compared to those treated with 6-MP. The study also identified factors associated with ePOR, including increased small bowel diameter, lower body mass index (BMI), and certain biomarker levels. The findings suggest that early initiation of adalimumab may be superior to 6-MP therapy in preventing ePOR in CD patients. [Extracted from the article] |
